Compare ABUS & SPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABUS | SPH |
|---|---|---|
| Founded | 2005 | 1945 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2008 | 1996 |
| Metric | ABUS | SPH |
|---|---|---|
| Price | $4.69 | $16.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 184.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 6.63% |
| EPS Growth | ★ 55.26 | 42.11 |
| EPS | 0.84 | ★ 2.48 |
| Revenue | $14,083,000.00 | ★ $1,432,518,000.00 |
| Revenue This Year | N/A | $2.06 |
| Revenue Next Year | $239.71 | $1.64 |
| P/E Ratio | ★ $5.71 | $6.63 |
| Revenue Growth | ★ 128.21 | 7.94 |
| 52 Week Low | $3.50 | $16.31 |
| 52 Week High | $5.45 | $20.80 |
| Indicator | ABUS | SPH |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 28.66 |
| Support Level | $4.42 | N/A |
| Resistance Level | $4.81 | $17.86 |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 16.48 | 9.68 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Suburban Propane Partners LP distributes propane, renewable propane, renewable natural gas (RNG), fuel oil, refined fuels, and markets natural gas and electricity in deregulated markets. It produces and invests in low-carbon fuel alternatives. The company installs and services home comfort heating and ventilation equipment and distributes fuel oil, kerosene, diesel, and gasoline to about 25,000 residential and commercial customers mainly in the U.S. northeast. It operates three segments: Propane, Fuel Oil and Refined Fuels, and Natural Gas and Electricity, with the Propane segment generating the majority of revenue. Propane, a by-product of natural gas processing and petroleum refining, is a clean-burning energy source known for transportability and ease of use.